Thomas Klockgether Selected Research

indium arsenide (InAs)

12/2020	Association of serum neurofilament light and disease severity in patients with spinocerebellar ataxia type 3.
9/2018	Long-term evolution of patient-reported outcome measures in spinocerebellar ataxias.
12/2016	Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study.
11/2015	Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study.
2/2015	Biological and clinical characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data.
3/2012	Spinocerebellar ataxia types 1, 2, 3 and 6: the clinical spectrum of ataxia and morphometric brainstem and cerebellar findings.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas Klockgether Research Topics

Disease

32	Ataxia (Dyssynergia) 01/2022 - 05/2004
19	Parkinson Disease (Parkinson's Disease) 01/2020 - 05/2002
17	Machado-Joseph Disease (Spinocerebellar Ataxia Type 3) 01/2022 - 10/2003
17	Spinocerebellar Ataxias (Spinocerebellar Ataxia) 01/2022 - 09/2004
14	Inflammation (Inflammations) 01/2020 - 04/2002
13	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 04/2002
10	Friedreich Ataxia (Friedreich's Ataxia) 01/2022 - 07/2008
10	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 10/2003
9	Disease Progression 01/2022 - 05/2003
7	Cerebellar Ataxia (Dysmetria) 01/2022 - 06/2011
6	Multiple Sclerosis 05/2012 - 02/2003
5	Dementia (Dementias) 01/2020 - 01/2011
4	Cognitive Dysfunction 01/2020 - 04/2003
4	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 05/2012 - 05/2003
3	Multiple System Atrophy 01/2022 - 01/2010
3	Lymphoma (Lymphomas) 12/2020 - 04/2003
3	Huntington Disease (Huntington's Disease) 01/2020 - 09/2006
3	Neuroblastoma 01/2012 - 10/2003
2	Atrophy 01/2022 - 06/2020
2	Movement Disorders (Movement Disorder) 01/2020 - 10/2003
2	Pain (Aches) 01/2016 - 09/2010
2	Mitochondrial Diseases (Mitochondrial Disease) 05/2011 - 06/2002
2	Autoimmune Diseases (Autoimmune Disease) 09/2009 - 01/2009
2	Sepsis (Septicemia) 09/2008 - 04/2007
2	Hypertension (High Blood Pressure) 11/2006 - 01/2005
2	Diabetes Mellitus 11/2006 - 01/2005
2	Adrenoleukodystrophy (Adrenoleukodystrophy, X-Linked) 10/2006 - 02/2003
2	Neoplasms (Cancer) 06/2006 - 08/2002
2	Amyloid Plaque 10/2005 - 06/2005
2	Glioma (Gliomas) 02/2003 - 06/2002
1	Ganglion Cysts (Ganglion) 01/2022
1	Breast Neoplasms (Breast Cancer) 06/2020
1	Hereditary Spastic Paraplegia 01/2020
1	Asthma (Bronchial Asthma) 01/2020
1	Leukoencephalopathies 01/2020
1	Dystonia (Limb Dystonia) 01/2020
1	Parkinsonian Disorders (Parkinsonism) 01/2020
1	Muscle Spasticity (Spastic) 01/2020
1	Chorea (Rheumatic Chorea) 01/2020
1	Frontotemporal Dementia (Semantic Dementia) 01/2020
1	Autoimmune Diseases of the Nervous System 01/2019

Drug/Important Bio-Agent (IBA)

14	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2010
11	Proteins (Proteins, Gene)FDA Link 01/2020 - 10/2003
10	polyglutamineIBA 11/2021 - 10/2003
9	Ataxin-3IBA 01/2022 - 10/2003
9	PPAR gammaIBA 09/2009 - 06/2002
7	Pharmaceutical PreparationsIBA 12/2021 - 05/2002
6	indium arsenide (InAs)IBA 12/2020 - 03/2012
5	DNA (Deoxyribonucleic Acid)IBA 09/2017 - 04/2005
5	Amyloid beta-PeptidesIBA 04/2006 - 04/2002
4	Retinaldehyde (Retinal)IBA 01/2022 - 03/2005
4	Interleukin-6 (Interleukin 6)IBA 10/2005 - 02/2003
3	IronIBA 01/2022 - 01/2010
3	salicylhydroxamic acid (SHAM)IBA 01/2022 - 07/2019
3	protein kinase C gamma (PRKCG)IBA 08/2020 - 02/2014
3	idebenoneIBA 06/2019 - 07/2008
3	AntibodiesIBA 01/2019 - 02/2003
3	Amyloid (Amyloid Fibrils)IBA 01/2017 - 10/2003
3	Biological ProductsIBA 02/2015 - 07/2013
3	Levodopa (L Dopa)FDA LinkGeneric 05/2009 - 05/2002
3	Dopamine (Intropin)FDA LinkGeneric 05/2009 - 06/2004
3	Transcription Factors (Transcription Factor)IBA 01/2009 - 10/2005
3	CytokinesIBA 09/2008 - 10/2003
3	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2006 - 10/2003
2	acetylleucineIBA 12/2021 - 01/2017
2	Cytarabine (Cytosar-U)FDA LinkGeneric 12/2020 - 04/2003
2	Methotrexate (Mexate)FDA LinkGeneric 12/2020 - 04/2003
2	N-Methylaspartate (NMDA)IBA 01/2019 - 05/2004
2	EnzymesIBA 09/2010 - 10/2005
2	factor V LeidenIBA 06/2010 - 06/2002
2	Factor XIII (Coagulation Factor XIII)IBA 06/2010 - 01/2005
2	CopperIBA 04/2010 - 09/2006
2	LigandsIBA 01/2009 - 10/2005
2	Interleukin-1beta (Interleukin 1 beta)IBA 09/2008 - 10/2005
2	Nicotine FDA Link 01/2008 - 01/2005
2	Lipoprotein(a)IBA 11/2006 - 01/2005
2	Cystathionine beta-Synthase (Serine Sulfhydrase)IBA 10/2006 - 10/2004
2	Glucose (Dextrose)FDA LinkGeneric 02/2006 - 08/2005
2	Pioglitazone (Actos)FDA Link 10/2005 - 06/2005
2	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 08/2005 - 10/2003
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 08/2003 - 04/2002
1	SodiumIBA 01/2022
1	Essential Amino AcidsIBA 12/2021
1	Tumor Necrosis Factor Ligand Superfamily Member 14IBA 12/2020
1	Protein Kinases (Protein Kinase)IBA 08/2020
1	anti-amphiphysin autoantibodyIBA 06/2020
1	Hexachlorobenzene (HCB)IBA 06/2020
1	Rivastigmine (Exelon)FDA LinkGeneric 01/2020
1	Mitochondrial Proteins (Mitochondrial Protein)IBA 01/2020
1	EsterasesIBA 01/2020
1	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2020
1	Niacinamide (Nicotinamide)FDA LinkGeneric 01/2019
1	AutoantibodiesIBA 01/2019
1	Immunoglobulin A (IgA)IBA 01/2019

Therapy/Procedure

9	Therapeutics 01/2020 - 06/2005
5	Activities of Daily Living (ADL) 01/2021 - 02/2006
5	Drug Therapy (Chemotherapy) 12/2020 - 08/2002
3	Transcranial Direct Current Stimulation 01/2022 - 07/2019
2	Radiotherapy 12/2003 - 04/2003
1	Duration of Therapy 12/2021